One of Roche’s spotlight PhIII cancer drug hopefuls stumbles in a key trial, with hit-and-miss results
Roche’s cancer team at Genentech has turned a few cards on their Phase III prostate cancer study for the AKT blocker ipatasertib, and they’re not all good to hold.
The Genentech crew spotlighted the positive, highlighting a success on progression-free survival in metastatic castration-resistant patients with PTEN loss. But the drug — delivered in combination with the standard of care combo abiraterone and prednisone/prednisolone compared to a SOC control arm — failed on PFS for the overall group in the IPATential150 trial, their other co-primary endpoint.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.